Prostate Cancer New Treatment | Biotech Strategy Blog

MDV3100 shows survival in Advanced Prostate Cancer

By Pieter Droppert on November 3, 2011

Prostate cancer is the second leading cause of cancer death in men, so it was good news this morning when Medivation & Astellas issued a press release that showed positive data from the phase 3 AFFIRM trial for MDV3100.

MDV3100 produced a 4.8-month advantage in median overall survival compared to placebo.

The estimated median survival for men treated with MDV3100 was 18.4 months compared with 13.6 months for men treated with placebo.

MDV3100 provided a 37 percent reduction in risk of death compared to placebo (Hazard Ratio=0.631).

This is a preview of MDV3100 shows survival in Advanced Prostate Cancer. Read the full post

American Urological Association Annual Meeting 2011 Satellite Symposia

By Pieter Droppert on May 12, 2011

I am off to Washington DC tomorrow for the annual meeting of the American Urological Association (AUA).

If you are not able to attend, then you can follow the Twitter coverage on Pharma Strategy Blog where Sally Church (@MaverickNY) will be aggregating the tweets. The conference hashtag is #AUA2011. I also expect to be live-tweeting from the conference.

Like many medical conferences in the United States, the AUA meeting kicks off with independent continuing medical education (CME) satellite symposia on topics of interest.

This is a preview of American Urological Association Annual Meeting 2011 Satellite Symposia. Read the full post

Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts tagged ‘Prostate Cancer New Treatment’

MDV3100 shows survival in Advanced Prostate Cancer